Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer
详细信息 查看全文
- 作者：Ken Kato (1) kenkato@ncc.go.jp
Keisho Chin (2)
Takaki Yoshikawa (3)
Kensei Yamaguchi (4)
Yasushi Tsuji (5)
Taito Esaki (6)
Kenji Sakai (7)
Masami Kimura (8)
Tetsuya Hamaguchi (1)
Yasuhiro Shimada (1)
Yasuhiro Matsumura (9)
Ryuji Ikeda (10) - 关键词：NK105 – ; Micellar nanoparticle – ; Phase II study – ; Gastric cancer – ; Second line
- 刊名：Investigational New Drugs
- 出版年：2012
- 出版时间：August 2012
- 年：2012
- 卷：30
- 期：4
- 页码：1621-1627
- 全文大小：155.1 KB
- 参考文献：1. GLOBOCAN database http://www-dep.iarc.fr/globocan/globocan.html.
2. Vital Statistics Japan (Ministry of Health, Labour and Welfare)
3. Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063–1069
4. Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435–1442
5. Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221
6. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study group. J Clin Oncol 24:4991–4997
7. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46
8. Hashimoto K, Takashima A, Nagashima K et al (2009) Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. J Cancer Res Clin Oncol 136:1059–1064
9. Thuss-Patience PC, Kretzschmar A, Deist T, et al (2009) Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol;27:15s, (suppl; abstr 4540).
10. Wilson D, Hiller L, Geh JI (2005) Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol 17:81–90
11. Wesolowski R, Lee C, Kim R (2009) Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol 10:903–912
12. Kodera Y, Ito S, Mochizuki Y et al (2007) Phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 27:2667–2671
13. Hironaka S, Zenda S, Boku N et al (2006) Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9:14–18
14. Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247–1259
15. Carney DN (1996) Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Semin Oncol 23:71–75
16. Crown J, O’Leary M (2000) The taxanes: an update. Lancet 355:1176–1178
17. Weiss RB, Donehower RC, Wiernik PH et al (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263–1268
18. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004–1014
19. Kloover JS, den Bakker MA, Gelderblom H et al (2004) Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 90:304–305
20. Hamaguchi T, Matsumura Y, Suzuki M et al (2005) NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 92:1240–1246
21. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392
22. Maeda H, Wu J, Sawa T et al (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284
23. Hamaguchi T, Kato K, Yasui H (2007) A Phase I and pharmacokinetic study of NK105, a paclitaxel -incorporating micellar nanoparticle formulation. Br J Cancer 97:170–176
24. Therasse P, Arbuck S, Eisenhauer E et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216
25. Common Terminology Criteria for Adverse Event (CTC-AE Version 3.0, March 31, 2003).
26. Green S, Dahlberg S (1992) Planned versus attained design in Phase II clinical trials. Stat Med 11:853–862
27. Tamura T, Sasaki Y, Nishiwaki Y, Saijo N (1995) Phase I study of paclitaxel by three-hour infusion: Hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 86:1203–1209
28. Boddy AV, Plummer ER, Todd R et al (2005) A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res 11:7834–7840
29. Ibrahim NK, Desai N, Legha S et al (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038–1044
30. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803 - 作者单位：1. Gastrointestinal Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, 104-0045 Tokyo, Japan2. Department of Cancer Chemotherapy, Cancer Institute Hospital Tokyo, Tokyo, Japan3. Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan4. Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan5. Department of Medical Oncology, Tonan Hospital, Sapporo, Japan6. Gastrointestinal Oncology and Medical Oncology Division, National Kyushu Cancer Center, Fukuoka, Japan7. Department of Medical Oncology, Saiseikai Kumamoto Hospital, Kumamoto, Japan8. Department of Surgery, Health Insurance Hitoyoshi General Hospital, Kumamoto, Japan9. Investigative Treatment Division, National Cancer Center Hospital East, Chiba, Japan10. Pharmaceutical Development, Nippon Kayaku Co., Ltd., Tokyo, Japan
- ISSN：1573-0646
文摘
Purpose NK105 is a new drug delivery system formulation for paclitaxel (PTX) whose recommended dose (RD) is 150 mg PTX equivalent/m2 administered every 3 weeks, as determined in a phase I trial. This study aimed to evaluate the efficacy and safety of NK105 in patients with advanced gastric cancer after failure of first-line chemotherapy. Experimental design Eligible patients had measurable disease and one chemotherapeutic regimen except taxane. NK105 (150 mg PTX equivalent/m2) was administered by a 30-minute intravenous infusion every 3 weeks without anti-allergic premedication until disease progression, unacceptable toxicity or patient refusal. The primary efficacy endpoint was best overall response rate (ORR) post baseline. The secondary endpoints were progression-free survival (PFS), time to treatment failure (TTF) and overall survival (OS). All adverse events were reported using CTCAE v3.0. Results Between November 2007 and July 2009, 57 patients were enrolled and 56 were evaluable for efficacy. Two complete responses and 12 partial responses were observed for an ORR of 25%. The median PFS was 3.0 months, the median TTF was 2.8 months, and the median OS was 14.4 months. Drug related toxicity was mainly mild (grades 1–2) to severe (grades 3–4); other data: neutropenia (64.9%); leukopenia (17.5%); lymphopenia (8.8%); neuropathy-sensory (1.8%); fatigue (3.5%); and stomatitis (1.8%). There were no treatment-related deaths. Conclusions This study of NK105 (150 mg PTX equivalent/m2) proves the concept for the modest activity and tolerability of a new drug delivery system formulation for PTX. A phase III trial will be evaluated to clarify survival benefit.